GlassScriptPhysician profile
Aamina Shakir
NPI 1750872594
$2,917.68
in general payments reported to CMS, 2019-2025
15 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $761 · 2023: $651 · 2024: $731 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $586.92 | 2021-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $468.35 | 2022-2024 | Lifevest |
| Medtronic, INC. | $231.98 | 2022-2025 | Harmony |
| Abbott Laboratories | $213.73 | 2021 | |
| W. L. Gore & Associates, INC. | $207.40 | 2024 | Gore Cardioform Septal Occluder |
| Amgen INC. | $167.87 | 2024-2025 | Repatha |
| Pfizer INC. | $144.66 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $143.35 | 2022-2024 | |
| Biosense Webster, INC. | $134.86 | 2025 | Carto 3, Nuvision Ice Catheter |
| Biotronik INC. | $133.86 | 2022 | |
| Daiichi Sankyo INC. | $125.00 | 2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $121.12 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $108.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $94.35 | 2022-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $35.43 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamina Shakir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.